When stratified by timing of treatment initiation , in participants enrolled 48 h or longer since illness onset , the median duration of symptoms was similar in both groups ( oseltamivir 3 days [ IQR 2-5 ] , placebo 3 days [ 1-5 ] ; p = 0.04 ) .